The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASCO 2021 | MRD by mass spectrometry in the peripheral blood in myeloma
Benjamin Derman, MD, University of Chicago, Chicago, IL, discusses the complimentary use of next generation sequencing (NGS) and mass spectrometry (MS) in the detection of measurable residual disease (MRD) in patients with multiple myeloma. Dr Derman reports that mass spectrometry and liquid chromatography are useful in the detection of paraprotein. Studies have identified a discordance in the detection of MRD by immunofixation and mass spectrometry, as well as between NGS in the bone marrow and mass spectrometry in the peripheral blood. Dr Derman also gives an overview of the MALDI-TOF mass spectrometry method and liquid chromatography, and compares the advantages and disadvantages of each. This interview took place at the virtual European Hematology Association (EHA) Congress 2021.
